WallStreetZenWallStreetZen

NASDAQ: TSHA
Taysha Gene Therapies Inc Stock Forecast, Predictions & Price Target

Analyst price target for TSHA

Based on 12 analysts offering 12 month price targets for Taysha Gene Therapies Inc.
Min Forecast
$1.50+110.08%
Avg Forecast
$6.21+769.47%
Max Forecast
$13.00+1,720.73%

Should I buy or sell TSHA stock?

Based on 12 analysts offering ratings for Taysha Gene Therapies Inc.
Buy
Strong Buy
5 analysts 41.67%
Buy
4 analysts 33.33%
Hold
3 analysts 25%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their TSHA stock forecasts and price targets.

TSHA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
Canaccord Genuity
Top 7%
94
Strong BuyMaintains$13.00+1,720.73%2023-02-01
Chardan Capital
Top 20%
81
Strong BuyMaintains$6.00+740.34%2023-02-01
Truist Securities
Bottom 14%
14
Strong BuyMaintains$4.00+460.22%2023-02-01
Cantor Fitzgerald
Top 4%
97
Strong BuyReiterates$13.00+1,720.73%2023-02-01
Jefferies
Bottom 8%
8
HoldDowngrades$1.50+110.08%2023-02-01
JMP Securities
Bottom 7%
7
BuyMaintains$4.00+460.22%2023-02-01
Baird
Bottom 1%
1
BuyMaintains$6.00+740.34%2023-02-01
Needham
Bottom 3%
3
BuyMaintains$6.00+740.34%2023-02-01
Morgan Stanley
Bottom 12%
12
HoldDowngrades$3.00+320.17%2023-01-27
Wells Fargo
Bottom 2%
2
Strong BuyMaintains$10.00+1,300.56%2023-01-04

1 of 2

Forecast return on equity

Is TSHA forecast to generate an efficient return?
Company
N/A
Industry
-0.1%
Market
28.88%

Forecast return on assets

Is TSHA forecast to generate an efficient return on assets?
Company
N/A
Industry
0.01%

TSHA earnings per share forecast

What is TSHA's earnings per share in the next 3 years based on estimates from 7 analysts?
Avg 1 year Forecast
-$2.65
Avg 2 year Forecast
-$2.62
Avg 3 year Forecast
-$1.52

TSHA revenue forecast

What is TSHA's revenue in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
$7.5M
Avg 2 year Forecast
$60.0M
Avg 3 year Forecast
$111.9M

TSHA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
TSHA$0.71$6.21+769.47%Buy
HOOK$0.81$4.50+456.24%Buy
NXTC$1.62$9.00+455.56%Strong Buy
BYSI$1.16$10.77+828.10%Hold
MGTA$0.76$4.33+470.13%Strong Buy

Taysha Gene Therapies Stock Forecast FAQ

Is Taysha Gene Therapies Stock a good buy in 2023, according to Wall Street analysts?

The consensus among 12 Wall Street analysts covering (NASDAQ: TSHA) stock is to Buy TSHA stock.

Out of 12 analysts, 5 (41.67%) are recommending TSHA as a Strong Buy, 4 (33.33%) are recommending TSHA as a Buy, 3 (25%) are recommending TSHA as a Hold, 0 (0%) are recommending TSHA as a Sell, and 0 (0%) are recommending TSHA as a Strong Sell.

If you're new to stock investing, here's how to buy Taysha Gene Therapies stock.

What is TSHA's earnings growth forecast for 2023-2025?

(NASDAQ: TSHA) Taysha Gene Therapies's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.24%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 19.48%.

Taysha Gene Therapies's earnings in 2023 is -$160,677,000.On average, 7 Wall Street analysts forecast TSHA's earnings for 2023 to be -$165,472,045, with the lowest TSHA earnings forecast at -$278,492,573, and the highest TSHA earnings forecast at -$93,038,999. On average, 3 Wall Street analysts forecast TSHA's earnings for 2024 to be -$163,598,776, with the lowest TSHA earnings forecast at -$187,326,843, and the highest TSHA earnings forecast at -$130,504,367.

In 2025, TSHA is forecast to generate -$94,912,267 in earnings, with the lowest earnings forecast at -$98,658,804 and the highest earnings forecast at -$91,165,730.

What is TSHA's revenue growth forecast for 2023-2025?

(NASDAQ: TSHA) Taysha Gene Therapies's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 40.95%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 8.76%.

Taysha Gene Therapies's revenue in 2023 is $0.On average, 2 Wall Street analysts forecast TSHA's revenue for 2023 to be $467,692,685, with the lowest TSHA revenue forecast at $404,001,558, and the highest TSHA revenue forecast at $531,383,811. On average, 2 Wall Street analysts forecast TSHA's revenue for 2024 to be $3,744,975,803, with the lowest TSHA revenue forecast at $933,512,101, and the highest TSHA revenue forecast at $6,556,439,505.

In 2025, TSHA is forecast to generate $6,985,730,187 in revenue, with the lowest revenue forecast at $1,448,036,496 and the highest revenue forecast at $12,523,423,877.

What is TSHA's forecast return on assets (ROA) for 2023-2026?

(NASDAQ: TSHA) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 0.01%.

What is TSHA's Price Target?

According to 12 Wall Street analysts that have issued a 1 year TSHA price target, the average TSHA price target is $6.21, with the highest TSHA stock price forecast at $13.00 and the lowest TSHA stock price forecast at $1.50.

On average, Wall Street analysts predict that Taysha Gene Therapies's share price could reach $6.21 by Feb 1, 2024. The average Taysha Gene Therapies stock price prediction forecasts a potential upside of 769.47% from the current TSHA share price of $0.71.

What is TSHA's Earnings Per Share (EPS) forecast for 2023-2025?

(NASDAQ: TSHA) Taysha Gene Therapies's current Earnings Per Share (EPS) is -$4.12. On average, analysts forecast that TSHA's EPS will be -$2.65 for 2023, with the lowest EPS forecast at -$4.46, and the highest EPS forecast at -$1.49. On average, analysts forecast that TSHA's EPS will be -$2.62 for 2024, with the lowest EPS forecast at -$3.00, and the highest EPS forecast at -$2.09. In 2025, TSHA's EPS is forecast to hit -$1.52 (min: -$1.58, max: -$1.46).

What is TSHA's forecast return on equity (ROE) for 2023-2026?

(NASDAQ: TSHA) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.